Hua Mao Wang
Founder bij CARSGEN THERAPEUTICS HOLDINGS LIMITED
Profiel
Hua Mao Wang is the founder of Shanghai Ruijin Biotechnology Co. Ltd.
(founded in 2011), CARsgen Therapeutics Holdings Ltd.
(founded in 2018), and Yijie Biotech Shanghai Holding Ltd.
(founded in 2011).
Dr. Wang's current jobs include Chief Operating Officer at CARsgen Therapeutics Co. Ltd.
(since 2014) and General Manager at Carsgen Diagnostics Co. Ltd.
(since 2020).
Dr. Wang received a graduate degree from Fudan University in 2003 and a doctorate degree from the same university in 2009.
Actieve functies van Hua Mao Wang
| Bedrijven | Functie | Begin |
|---|---|---|
| CARSGEN THERAPEUTICS HOLDINGS LIMITED | Founder | 09-02-2018 |
CARsgen Therapeutics Co. Ltd.
 CARsgen Therapeutics Co. Ltd. BiotechnologyHealth Technology CARsgen Therapeutics Co., Ltd. develops an immunotherapy cancer treatment. It develops a novel cell-based immunotherapy using T-cells carrying chimeric antigen receptor technology for cancer treatment. The company was founded by ZongHai Li in 2014 and is headquartered in Shanghai, China. | Chief Operating Officer | 01-10-2014 |
| Carsgen Diagnostics Co. Ltd. | Chief Executive Officer | 01-11-2020 |
Eerdere bekende functies van Hua Mao Wang
| Bedrijven | Functie | Einde |
|---|---|---|
| Shanghai Ruijin Biotechnology Co. Ltd. | Founder | 01-01-2013 |
| Yijie Biotech Shanghai Holding Ltd. | Chief Executive Officer | 01-10-2014 |
Opleiding van Hua Mao Wang
| Fudan University | Graduate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Beursgenoteerde bedrijven | 1 |
|---|---|
| CARSGEN THERAPEUTICS HOLDINGS LIMITED | Health Technology |
| Bedrijven in privébezit | 4 |
|---|---|
CARsgen Therapeutics Co. Ltd.
CARsgen Therapeutics Co. Ltd. BiotechnologyHealth Technology CARsgen Therapeutics Co., Ltd. develops an immunotherapy cancer treatment. It develops a novel cell-based immunotherapy using T-cells carrying chimeric antigen receptor technology for cancer treatment. The company was founded by ZongHai Li in 2014 and is headquartered in Shanghai, China. | Health Technology |
| Yijie Biotech Shanghai Holding Ltd. | |
| Shanghai Ruijin Biotechnology Co. Ltd. | |
| Carsgen Diagnostics Co. Ltd. |
